Quote:

---

If at 42 days the separation between recovery and worsening grows greater, the 2 dose might be more compelling. If the difference does not grow, more subsequent doses likely needed. They are likely wanting info on direction for doctors to know how many doses are needed and when more are needed depending on the patient’s recovery.

---

I might be misunderstanding you, but just to be clear, there was no change made to the dosing schedule of the protocol.

Sadly, it remains at a total of 2 (two) doses -- one at Day 0 and one at Day 7. As mentioned in an earlier post, I wish our protocol had patients receiving leronlimab for the entire 28 days of the trial.

Why base mortality on just two doses? The goal of this trial is to find out if leronlimab works -- not to find out if it works with only two stingy doses.

https://investorshangout.com/post/view?id=5941141